BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:RO7851624 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of RO7851624\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07558915-3316@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:RO7851624: Phase 1 readout est. (NCT07558915)
DESCRIPTION:RO7851624\, phase 1\, Multiple Myeloma.\nStudy: A Study to Eval
 uate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (
 RRMM)\nEstimated primary completion: 1 July 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ro7851624#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07558915
URL:https://assetmemo.bio/drug/ro7851624#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
